MedTrace Logo

Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients

NCT06585761 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-09-05

No results posted yet for this study

Summary

The aim of this study is to explore the effect of SGLT2i on the levels of cardiac biomarkers, inflammatory and stress markers in Egyptian heart failure patients to provide a better understanding of mechanism that might assist in tailoring treatment strategies in patients with various forms of HF especially in Egyptian population. Also understand how biomarkers may be employed to predict risk in patients receiving SGLT2i or identification of those who may derive the most benefit from SGLT2i in the means of individualized medicine.

Conditions

Interventions

DRUG

SGLT2 inhibitor

patients with HF are subjected to regular dose of SGLT2I member according to patient status.

DEVICE

echo cardiogram

the patients are subjected to ECHO to determine their EF prior to and post the study

Sponsors & Collaborators

  • Kafrelsheikh University

    lead OTHER

Principal Investigators

  • Nada Nabil Mohammed Elsalhey, Bsc · clinical pharmacy department, kafrelsheikh university

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2025-06-30
Completion
2025-06-30
FDA Device
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06585761 on ClinicalTrials.gov